Inhibikase Therapeutics, Inc.
IKT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001750149
No open-market purchases or sales by Inhibikase Therapeutics, Inc. insiders were filed in the last 90 days; 105 institutions reported holding it in 13F filings for Q2 2026, worth $239.2M in total; no superinvestor holds it.
13F holders, Q4 2023
Institutional positions in Inhibikase Therapeutics, Inc. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 11
- −2 vs. Q3 2023
- Shares held
- 235.0K
- −194.7K (−45.3%) vs. Q3 2023
- Total value
- $298.9K
- −$298.7K (−50.0%) vs. Q3 2023
- New holders
- 2
- 3 more added
- Sold out
- 4
- 3 more reduced
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting IKT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 105 | $239.2M |
| Q1 2026 | 104 | $193.4M |
| Q4 2025 | 74 | $218.2M |
| Q3 2025 | 54 | $89.0M |
| Q2 2025 | 48 | $106.3M |
| Q1 2025 | 47 | $112.7M |
| Q4 2024 | 31 | $162.7M |
| Q3 2024 | 11 | $1.12M |
| Q2 2024 | 12 | $1.02M |
| Q1 2024 | 12 | $443.8K |
| Q4 2023 | 11 | $298.9K |
| Q3 2023 | 13 | $597.6K |
| Q2 2023 | 14 | $2.69M |
| Q1 2023 | 17 | $2.91M |
| Q4 2022 | 19 | $719.4K |
| Q3 2022 | 24 | $2.78M |
| Q2 2022 | 22 | $2.49M |
| Q1 2022 | 24 | $6.33M |
| Q4 2021 | 26 | $6.85M |
| Q3 2021 | 21 | $7.78M |
| Q2 2021 | 14 | $10.6M |
| Q1 2021 | 9 | $975.0K |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Inhibikase Therapeutics, Inc.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 82,045 | $104.2K | 0.00% | −5,402−6.2% | Reduced |
| Blair William & Co | 60,268 | $76.5K | 0.00% | +893+1.5% | Added |
| Geode Capital Management, LLC | 28,692 | $36.5K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 24,422 | $31.0K | 0.00% | +8,300+51.5% | Added |
| Redmond Asset Management, LLC | 19,644 | $24.9K | 0.01% | −1,333−6.4% | Reduced |
| State Street Corp | 10,084 | $12.8K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 5,919 | $7.52K | 0.00% | +3,719+169.0% | Added |
| Royal Bank of Canada | 2,000 | $3.00K | 0.00% | +2,000 | New |
| Morgan Stanley | 1,667 | $2.12K | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 201 | $255 | 0.00% | −31−13.4% | Reduced |
| Bank of America Corp | 62 | $79 | 0.00% | +62 | New |
| Armistice Capital, LLC | 0 | $0 | 0.00% | −186,046−100.0% | Sold out |
| Edgewood Management LLC | 0 | $0 | 0.00% | −16,666−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −149−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −5−100.0% | Sold out |